ABSTRACT
Sex chromosome aneuploidies (SCAs), including 47,XXY, 47,XXX, 47,XYY, and supernumerary variants, occur collectively in approximately 1/500 livebirths. Clinical phenotypes are highly variable resulting in previous ascertainment rates have been estimated to be only 10-25% during a lifetime. Historically, prenatal SCA diagnoses were incidental findings, accounting for ≤10% of cases, with the majority of diagnoses occurring postnatally during evaluations for neurodevelopmental, medical, or infertility concerns. The initiation of noninvasive prenatal testing (NIPT) in 2012 and adoption into standardized obstetric care provides a unique opportunity to significantly increase prenatal ascertainment of SCAs. However, the impact NIPT has had on ascertainment of SCAs is understudied, particularly for those who may defer diagnostic testing until after birth. This study evaluates the timing of diagnostic testing following positive NIPT in 152 infants with SCAs and potential factors influencing this decision. Eighty-seven (57%) elected to defer diagnostic testing after a positive NIPT until birth, and 8% (7/87) of those confirmed after birth were found to have discordant results on postnatal diagnostic testing, most of which would have influenced genetic counseling.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by NIH/NINDS K23NS070337 and NIH/NICHD 2RO1-HD42974. Contents are the authors sole responsibility and do not necessarily represent official NIH views.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Colorado COMIRB #17-0118 of the University of Colorado and Nemours Office of Human Subjects Protection of Nemours IRB#1151006 gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
SOURCES OF SUPPORT: National Institute of Child Health and Human Development (NIH/NICHD) R01HD42974
National Institute of Child Health and Human Development (NIH/NICHD), K23HD092588
National Institute of Neurological Disorders and Stroke (NIH/NINDS), K23NS070337
National Center for Advancing Translational Sciences (NIH/NCATS) Colorado CTSA UL1TR002535
DISCLOSURE SUMMARY: The authors have nothing to disclose.
Data Availability
Deidentified data that support the findings of this study are available from the corresponding author upon reasonable request.
